Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?

Christos Fountzilas, Selena Stuart, Brian Hernandez, Elizabeth Bowhay-Carnes, Joel E Michalek, John Sarantopoulos, Anand B Karnad, Sukeshi Patel, Steven D Weitman, Devalingam Mahalingam

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Summary: Introduction The goal of organ dysfunction Phase I trials is to characterize the safety and pharmacokinetics of novel agents in cancer patients with liver or kidney dysfunction, but the clinical benefit is not well established. Methods We reviewed 170 patients across 15 liver dysfunction studies at our institution, grouped based on the NCI-Organ Dysfunction Working Group criteria or Child-Pugh Score. Results The median survival for the entire cohort was two months and just one month amongst patients with severe liver dysfunction. Patients with normal or mild liver dysfunction, absence of tumor in liver, good performance status, higher serum albumin and lower bilirubin, aspartate transaminase and alkaline phosphatase had improved survival by univariate analysis. Serum albumin and liver function classification remained significant by multivariate analysis. Conclusion Given poor survival of patients with liver dysfunction, we need better criteria, such as albumin levels, for optimally selecting patients for liver dysfunction studies.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalInvestigational New Drugs
DOIs
StateAccepted/In press - Jan 19 2017

Keywords

  • Liver dysfunction
  • Phase I study
  • Prognostic model
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?'. Together they form a unique fingerprint.

Cite this